Arlene Siefker-Radtke
Overview
Explore the profile of Arlene Siefker-Radtke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
4185
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat A, Alhalabi O, et al.
Hum Pathol
. 2024 Apr;
148():1-6.
PMID: 38679207
Plasmacytoid urothelial carcinoma (UC) is a rare histologic subtype of bladder cancer that is associated with an aggressive clinical behavior. We analyzed the clinicopathologic and molecular features of plasmacytoid UC...
2.
Necchi A, Ramlau R, Falcon Gonzalez A, Chaudhry A, Todenhofer T, Tahbaz R, et al.
JNCI Cancer Spectr
. 2024 Apr;
8(3).
PMID: 38627238
Background: This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients...
3.
Fleming S, Gifkins D, Resnick H, Shalaby W, Rosenberg P, Gaj C, et al.
Clin Genitourin Cancer
. 2024 Mar;
22(3):102054.
PMID: 38457853
Introduction: Evidence is limited on whether fibroblast growth factor receptor gene alterations (FGFRalt) impact clinical outcomes in patients with locally advanced or metastatic urothelial cancer (mUC). This study evaluated progression-free...
4.
Msaouel P, Sweis R, Bupathi M, Heath E, Goodman Jr O, Hoimes C, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):933-943.
PMID: 38105142
Background And Objective: Checkpoint inhibitor therapy (CPI) has demonstrated survival benefits in urothelial carcinoma (UC); however, not all patients benefit from CPI due to resistance. Combining sitravatinib, a multitargeted receptor...
5.
Zaleski M, Chen H, Roy-Chowdhuri S, Patel K, Luthra R, Routbort M, et al.
Am J Clin Pathol
. 2022 Apr;
158(2):263-269.
PMID: 35467000
Objectives: To investigate the gene mutational profile of urachal carcinoma in correlation with its clinicopathologic features. Methods: We analyzed genetic mutations in 30 cases of urachal carcinoma by next-generation sequencing...
6.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, et al.
Nat Commun
. 2022 Apr;
13(1):1797.
PMID: 35379845
Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAP) in tumors with 9p21 loss and hypothetically renders tumors susceptible to synthetic lethality by antifolates targeting...
7.
Adibi M, McCormick B, Economides M, Petros F, Xiao L, Guo C, et al.
Clin Genitourin Cancer
. 2022 Jan;
20(2):176-182.
PMID: 35039231
Background: Emerging data suggests improved outcomes in patients receiving neoadjuvant chemotherapy (NAC) prior to radical nephroureterectomy (RNU) for high-risk upper tract urothelial carcinoma. In one of the largest single-center experiences...
8.
Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang R, et al.
Eur Urol Oncol
. 2021 Nov;
6(2):228-232.
PMID: 34789422
Deficiency of MTAP (MTAP) mainly occurs because of homozygous loss of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC). We characterized the clinical and...
9.
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson B, et al.
Nat Commun
. 2021 Sep;
12(1):5606.
PMID: 34556668
Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance...
10.
Alhalabi O, Hahn A, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, et al.
Clin Genitourin Cancer
. 2021 Aug;
20(1):e16-e24.
PMID: 34362693
Introduction: Enrolling patients with metastatic urothelial carcinoma (mUC) in phase I trials provides an opportunity to identify biological drug activity. Developing prognostic scores may aid in patient selection for phase...